Member Info for lawdoc

Share magazine have tipped QXT again. "Revenue rose 31% to $36.5 million and included a 55% improvement in the company’s gaming division."
Their recommendation "More to come. Keep buying."

Why 50% share price upside could be on the cards at Quixant. This is the title of the two page article on Quixant in this weeks Share Magazine.
Recommendation: Buy. implies a 275p share price over the next 12 to 18 months, or 56% upside.

Yes, very good results.
An encouraging reference to Virolens but no mention of costs incurred, or an initial order.
" The Virolens COVID-19 screening device achieved its first important regulatory milestone in H1, gaining registration with the MHRA in Great Britain. We have now established a product with commercial potential and remain encouraged that active dialogue is continuing with a number of regulators and that commercial potential exists with a range of customers subject to further approvals."

Hi,
I was about to dip my toe into EKF on this coming Monday having tracked EKF for a while. The article in the ST today suggests take profits like the EKF Chairman. I quite understand the Chairs need to diversify his portfolio, however, it begs the question - am I too late to significantly benefit from EKF gains as presumably the Chair thinks so?

Recommended by Share Magazine today as a way to beat the taxman on Inheritance Tax. It is eligible for BPR and to quote their words: "Alliance Pharma is targeting double-digit revenue and profit growth over the next three to five years."

I am surprised that most of the Sunday papers have not picked this up. After the FT gave Virolens poor PR in Sept '20, now that the MHRA has approved Virolens manufactured by TTG you would think the FT would at least accept they got it wrong and publicise this British technology.

On the Collinson website it suggests "The UK is now in the position to benefit from the experience of other markets and implement inbound PCR testing to safely restart more of the travel sector including ‘red’ listed countries and long-haul routes. "

Can someone update me on whose PCR tests Collinson and Swissport intend to use at Heathrow? It would seem that testing at T2 is likely to start at month-end.

Thanks.

An article in The Times today by Alex Ralph. (Incase it is of interest and not been posted earlier)

The UK-listed biotech company working closely with the government and big pharma to mass-produce diagnostic coronavirus tests has launched three new products to boost the process.

Novacyt said they would support laboratories by accelerating the production of tests and by addressing the shortage of a key component. ..............

Shares Magazine picks its 10 winning stocks for 2020. Begbies is one of them.
"Martin says: Increasing insolvencies are a boon to specialist practitioner Begbies Traynor"
It is suggested that Begbies is attractive as an investment in both an economic downturn and upturn so I have added to my holding.
Merry X'mas!

From The Sunday Times by Rachel Millard ' Inside the City'.
https://www.thetimes.co.uk/article/serica-to-enjoy-fruits-of-north-sea-t6082s3gk

EPS up in sterling terms that will represent an increase of 65% over the comparable period and by 91% in rand, slashed Debt and great Dividend - Can't ask for more. Well done PAF.

If only LMI would do the same with its recovery plans....

Laird is one of the five listed in the UK.

Target 355p, Divi at 5%.

ATB